1 |
Coffin CS, Haylock-Jacobs S, Doucette K, Ramji A, Ko HH, Wong DK, Elkhashab M, Bailey R, Uhanova J, Minuk G, Tsoi K, Wong A, Ma MM, Tam E, Brahmania M, Nudo C, Zhu J, Lowe CF, Osiowy C, Lethebe BC, Congly SE, Chan EKH, Villasis-Keever A, Sbarigia U, Cooper CL, Fung S. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA). Viruses 2022;14. [PMID: 36560672 DOI: 10.3390/v14122668] [Reference Citation Analysis]
|
2 |
Azhari H, Frolkis AD, Shaheen AA, Israelson H, Pinto J, Congly SE, Borman MA, Aspinall AA, Stinton LM, Nguyen HH, Swain MG, Burak KW, Lee SS, Sadler MD, Coffin CS. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. CanLivJ 2022. [DOI: 10.3138/canlivj-2022-0002] [Reference Citation Analysis]
|
3 |
Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
4 |
Gao L, Hu Y, Shi X, Li X, Zhang D, Ren H. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Ann Hepatol 2020;19:329-34. [PMID: 31884016 DOI: 10.1016/j.aohep.2019.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
5 |
Patel NH, Joshi SS, Lau KCK, Castillo E, Coffin CS. Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers. J Clin Virol 2019;111:42-7. [PMID: 30639847 DOI: 10.1016/j.jcv.2019.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|